As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Skye Bioscience, Inc. The largest reported stake is 5AM Partners VII, LLC's, at 26.1%. 5 filings are on record since August 14, 2025 (Schedule 13D/A, September 24, 2026).
Sell to companies like Skye Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 263,560 · Sole dispositive: 0 · Shared dispositive: 263,560 · SCHEDULE 13G, 2026-10-14
- · Reporting person: 5AM Partners VII, LLC · Sole voting: 0 · Shared voting: 1,194,443 · Sole dispositive: 0 · Shared dispositive: 1,194,443 · SCHEDULE 13D/A, 2026-09-24
- · Holder: 5AM Partners VII, LLC · Percent: 30.2% · SCHEDULE 13D/A
- · Holder: 5AM Partners VII, LLC · Percent: 34% · SCHEDULE 13D/A
- · Holder: Schonfeld Strategic Advisors LLC · Percent: 3.6% · SCHEDULE 13G/A
Skye Bioscience, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, par value $0.001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5AM Partners VII, LLC | 26.1% | 1,194,443 | SCHEDULE 13D/A, 2026-09-24 | 2026-09-22 |
| Tang Capital Management, LLC | 6% | 263,560 | SCHEDULE 13G, 2026-10-14 | 2026-10-07 |
| Schonfeld Strategic Advisors LLC | 3.6% | 1,115,939 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Skye Bioscience, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Skye Bioscience, Inc. and the records around it.
Skye Bioscience, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- 5AM Partners VII, LLC also filed stake reports on 1 other company: Surrozen, Inc. (Aug 2026)
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Inhibrx Biosciences, Inc. (Aug 2026), Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026), Capricor Therapeutics, Inc. (Aug 2026)
Watch Skye Bioscience, Inc.
Get an email when Skye Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Skye Bioscience, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Skye Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Skye Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| 5AM Partners VII, LLC | 0 | 1,194,443 | 0 | 1,194,443 | SCHEDULE 13D/A, 2026-09-24 |
| 5AM Ventures VII, L.P. | 0 | 1,194,443 | 0 | 1,194,443 | SCHEDULE 13D/A, 2026-09-24 |
| 5AM Partners II, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-24 |
| 5AM Ventures II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-24 |
| 5AM Co-Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-24 |
| Andrew J. Schwab | 23,645 | 1,194,443 | 23,645 | 1,194,443 | SCHEDULE 13D/A, 2026-09-24 |
| Kush Parmar | 0 | 1,194,443 | 0 | 1,194,443 | SCHEDULE 13D/A, 2026-09-24 |
| John D. Diekman | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-24 |
| Scott M. Rocklage | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-09-24 |
| Tang Capital Management, LLC | 0 | 263,560 | 0 | 263,560 | SCHEDULE 13G, 2026-10-14 |
| Kevin Tang | 0 | 263,560 | 0 | 263,560 | SCHEDULE 13G, 2026-10-14 |
| Tang Capital Partners, LP | 0 | 60,000 | 0 | 60,000 | SCHEDULE 13G, 2026-10-14 |
| Tang Capital Partners International, LP | 0 | 83,556 | 0 | 83,556 | SCHEDULE 13G, 2026-10-14 |
| Tang Capital Partners Iii, Inc | 0 | 60,002 | 0 | 60,002 | SCHEDULE 13G, 2026-10-14 |
| Tang Capital Partners Iv, Inc | 0 | 60,002 | 0 | 60,002 | SCHEDULE 13G, 2026-10-14 |
The latest filing identifies Skye Bioscience, Inc. by CUSIP 83086J309 and gives its principal executive office as 11250 El Camino Real, Suite 100, San Diego, CA 92130 (SCHEDULE 13G, 2026-10-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Schonfeld Strategic Advisors LLC | 3.6% | SCHEDULE 13G/A |
| 2025-12-16 | 5AM Partners VII, LLC | 34% | SCHEDULE 13D/A |
| 2026-08-18 | 5AM Partners VII, LLC | 30.2% | SCHEDULE 13D/A |
| 2026-09-24 | 5AM Partners VII, LLC | 26.1% | SCHEDULE 13D/A |
| 2026-10-14 | Tang Capital Management, LLC | 6% | SCHEDULE 13G |
Questions about who owns Skye Bioscience, Inc.
Who owns Skye Bioscience, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Skye Bioscience, Inc.: 5AM Partners VII, LLC (26.1%, Schedule 13D/A, filed 2026-09-24) and Tang Capital Management, LLC (6%, Schedule 13G, filed 2026-10-14).
Who are the largest shareholders of Skye Bioscience, Inc.?
By the share each holder's latest filing reports, the largest holders of Skye Bioscience, Inc. on this page are 5AM Partners VII, LLC (26.1%) and Tang Capital Management, LLC (6%).
When did 5AM Partners VII, LLC buy into Skye Bioscience, Inc.?
The filings give report dates, not purchase dates. The earliest filing from 5AM Partners VII, LLC on this page is the Schedule 13D/A, filed 2025-12-16, reporting 34%; its latest, Schedule 13D/A filed 2026-09-24, reports 26.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Skye Bioscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 11, 2026 | Leadership change: John P. Sharp departs, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| April 3, 2026 | Leadership change: John P. Sharp appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Skye Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.